AUTHORS
Maria Pardo, Chad A. Hudson, MD, Ph.D2, Andrew J. Menssen, Ph.D., HCLD(ABB)3, Fan-Chi Hsu, PhD4, Loren L. Lott5, Rhonda E. Ries, MA6, Jack H. Peplinski, MSc7, Katherine Tarlock I, MD8, Lisa Eidenschink Brodersen, PhD9, Quy LE10, Danielle C. Kirkey, MD11, Todd Cooper I, DO12, Jessica A. Pollard I, MD13, Jay Sarthy, MD, PhD14, Brandon Hadland, MD, PhD15, Takashi Ishida16, Michael Loken, PhD17, Soheil Meshinchi, MD, PhD18
AFFILIATIONS
1 Hematologics, Inc., Seattle, Washington, United States
2 Hematologics, Inc., Seattle, Washington, United States
3 Hematologics, Inc., Seattle, Washington, United States
4 Hematologics, Inc., Seattle, Washington, United States
5 Hematologics, Inc., Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Seattle Children's Hospital, Seattle, Washington, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 CHOC Hospital & Clinic, Orange, California, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Seattle Children's Hospital, Seattle, Washington, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Seattle Children's Hospital, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States
17 Hematologics, Inc., Seattle, Washington, United States
18 Fred Hutchinson Cancer Center, Seattle, Washington, United States
ABSTRACT
Introduction: CBFA2T3::GLIS2-positive AML (CBF/GLIS), previously defined phenotypically as RAM AML, is a distinct infant and young childhood AML subtype with an exceptionally poor response to conventional chemotherapy. We previously established RAM AML as the phenotypic counterpart of CBF/GLIS AML with complete concordance and identified FOLR1 as the first AML-restricted antigen translated into clinical-stage immunotherapy (Tarlock et. al, ASH 2026). Because antigen escape remains a major challenge, we evaluated additional therapeutic targets in RAM AML. We investigated CD371 (CLEC12A gene), CD70, and mesothelin. Like FOLR1, CD70 and mesothelin are AML-restricted targets whereas CD371 is a common myeloid antigen. Cellular therapies for all three are under way. To investigate the potential feasibility of these antigens in the treatment of RAM AML, we examined their expression on the abnormal myeloid progenitor cells (abMPC) of RAM AML patients.
Methods: As part of COG AML trials, we prospectively evaluated CD371, CD70, and mesothelin expression on the abMPC of 19 patients with CBF/GLIS+ / RAM-AML and compared to the abMPC of 281 patients with other types of AML. All 19 diagnostic specimens were centrally and prospectively evaluated for the expression of common AML antigens as well as CD371, CD70, and mesothelin by multi-dimensional flow cytometry (MDF) at Hematologics, Inc. The abMPC of RAM cases were selected based on CD45 and CD38 expression.
Results: Of the 1259 patients with full diagnostic flow data, 19 patients met the definitive diagnosis of RAM phenotype (1.5%) and molecular diagnosis of CBFA2T3::GLIS2 was made with confirmatory RT-PCR assay. As expected, in the entire cohort, CD371, CD70, and mesothelin were variably expressed in non-RAM AML with 83% expressing CD371, 19% expressing mesothelin, and 14% expressing CD70. Detailed characteristics of CD371, CD70 and mesothelin are presented elsewhere. Expression of these three experimental antigens were evaluated in the 19 cases of RAM phenotype. Remarkably, despite ubiquitous expression of CD371 in normal hematopoiesis, this antigen was entirely absent in the RAM AML cases, arguing that this gene is silenced as part of malignant transformation at the stem cell stage. Direct comparison of the CLEC12A (gene counterpart to CD371) transcript expression in 38 RAM cases to that of 68 normal bone marrow (NBM) validated this observation. Median CLEC12A transcript in the 38 RAM cases was 3.1 TPM (range 0.4-80.2), vs. that of 43.3 TPM (range 7.4-109.2) in NBM (P<0.001), validating transcriptional silencing of CD371 in RAM AML. Methylation studies comparing NBM to RAM cases demonstrated anti-correlation of promoter methylation and CLEC12A expression, providing clear evidence that CLEC12A silencing is secondary to promoter hypermethylation. In contrast, CD70, which is entirely absent in normal hematopoiesis, was expressed in 4 patients (21%) demonstrating induction of expression. Similarly, transcript studies showed induction of CD70 expression with 16% of RAM patients with significant CD70 transcript expression. CD70 transcript was entirely silent in the 68 cases of NBM tested (TPM range 0.03-0.78). Chromatin profiling and transcriptomic analyses in engineered cord blood demonstrated that CD70 locus is completely silenced by Polycomb repressive complex in normal cord blood cells, whereas in CBF/GLIS transduced cells, this locus is de-repressed, allowing expression of CD70. Moreover, in engineered CBF/GLIS-AML, CD70 expression by scRNA-seq correlated with stemness-associated gene programs and resistance-linked signaling pathways, and endothelial niche cells conferred cytarabine resistance while selectively enriching CD70? cells, implicating CD70 as a marker of microenvironment-mediated chemoresistance. Mesothelin, an AML-restricted antigen was absent in all RAM AML cases.
Conclusion: RAM/CBFA2T3::GLIS2 AML undergoes profound antigen remodeling characterized by epigenetic silencing of the myeloid antigen CD371 together with de novo activation of CD70 in a subset of cases, while lacking mesothelin expression. These findings identify distinct mechanisms governing therapeutic antigen expression in this leukemia and provide a rational framework for selecting antigen-directed immunotherapies beyond FOLR1. Systematic integration of immunophenotypic, transcriptomic, and epigenetic profiling represents a powerful strategy for precision target discovery in AML.
DISCLOSURES
Maria Pardo: Hematologics Inc - Current Employment; Fred Hutchinson Cancer Center - Current Employment